Orris

Type 1 and type 2 diabetes respect to physiology

Reading File
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
I now have comprehensive, high-quality content from multiple authoritative textbooks. Let me compile the full answer.

Type 1 vs. Type 2 Diabetes: Physiology

Overview

Diabetes mellitus encompasses a group of metabolic disorders all sharing the common feature of chronic hyperglycemia, but the underlying physiological mechanisms differ fundamentally between Type 1 and Type 2.

Normal Insulin Physiology (Background)

The pancreatic beta (β) cells in the islets of Langerhans act as glucose sensors. When blood glucose rises postprandially, glucose enters β cells via GLUT-2 transporters, is phosphorylated by glucokinase (the "glucose sensor"), enters glycolysis, raises the ATP/ADP ratio, closes ATP-sensitive K+ channels, depolarizes the membrane, opens voltage-gated Ca²+ channels, and triggers insulin exocytosis. Insulin then acts on liver, muscle, and adipose tissue to:
  • Promote glycogenesis (inhibits glycogen phosphorylase, activates glycogen synthase)
  • Promote glycolysis (induces glucokinase, fructose-2,6-bisphosphate, pyruvate kinase, pyruvate dehydrogenase)
  • Inhibit gluconeogenesis (suppresses PEPCK gene; fructose-2,6-bisphosphate inhibits fructose-1,6-bisphosphatase)
  • Inhibit glucose-6-phosphatase, blocking hepatic glucose output
  • Stimulate GLUT-4 translocation in muscle and fat for glucose uptake
  • Medical Physiology, Boron & Boulpaep, p. 3592-3613

Type 1 Diabetes Mellitus

Definition and Epidemiology

Type 1 DM accounts for 5-10% of all diabetes cases and peaks in onset at 11-12 years of age. It is characterized by absolute insulin deficiency resulting from immune-mediated destruction of pancreatic β cells.
  • Henry's Clinical Diagnosis and Management, p. 269

Core Pathophysiology: Autoimmune β-Cell Destruction

The central mechanism is a T cell-mediated autoimmune attack on β cells (insulitis):
  • CD4+ Th1 cells recognize islet antigens (including insulin itself) and drive inflammation
  • CD8+ cytotoxic T lymphocytes (CTLs) directly lyse β cells
  • Cytokines - TNF and IL-1 released locally damage islet cells
  • Autoantibodies against islet components are produced (though they may not be the primary destructive mechanism)
The pancreatic lesion shows cellular necrosis and lymphocytic infiltration by both CD4+ and CD8+ T cells - this is called insulitis. Because of the enormous functional reserve of the pancreas, 90% or more of the islets must be destroyed before clinical diabetes manifests. This explains the long prodromal period (months to years) before diagnosis.
  • Cellular and Molecular Immunology, Abbas et al., p. 1286-1287

Autoantibody Markers

Detectable autoantibodies precede and predict overt disease. Key autoantibodies:
AutoantibodyTargetNotes
GAD65Glutamic acid decarboxylase (65 kDa)Highest sensitivity (91%) as single screening marker
IAAInsulinMore common in young children
IA-2 / IA-2ATyrosine phosphatase-related proteinOn β-cell secretory granule membrane
ZnT8AZinc transporter 8On β-cell secretory granule membrane
The presence of two or more autoantibodies significantly predicts progression to Type 1 DM.
  • Henry's Clinical Diagnosis, p. 269-270

Genetic Susceptibility

  • HLA genes are the strongest genetic risk factor: 90-95% of Caucasian patients carry HLA-DR3 or DR4 (vs. ~40% of healthy subjects). HLA-DQ alleles in linkage disequilibrium with these DR alleles may be the actual functional risk genes.
  • Non-HLA genes include the insulin gene promoter (tandem repeat polymorphisms affecting thymic insulin expression, which determines whether insulin-reactive T cells are deleted during maturation), as well as polymorphisms in IL-2 and CD25 (IL-2 receptor α-chain), affecting T regulatory cell (Treg) function.
  • Cellular and Molecular Immunology, p. 1287

Environmental Triggers

Viral infections (e.g., coxsackievirus B4) may initiate β-cell injury, induce expression of costimulatory molecules, and trigger autoimmunity via molecular mimicry. Paradoxically, epidemiological evidence (the "hygiene hypothesis") suggests that repeated childhood infections may be protective against Type 1 DM.

Metabolic Consequences of Absolute Insulin Deficiency

With the complete loss of insulin but preservation of glucagon (the α cells are spared), Type 1 DM physiologically resembles an accelerated fasting or starvation state:
  • Normally, even during prolonged fasting, a small amount of insulin is secreted to counterbalance glucagon. In Type 1 DM, this balance is completely lost.
  • Unopposed glucagon action drives:
    • Unrestricted hepatic gluconeogenesis → progressive hyperglycemia
    • Unrestricted hepatic ketogenesis from free fatty acids → ketone body accumulation
    • Accelerated lipolysis and protein catabolism
  • Glucose and ketone production far exceeds peripheral utilization
  • Even at glucose concentrations 5-10 times normal, no insulin is secreted (β cells are absent)
  • The massive solute load causes osmotic diuresis, dehydration, and electrolyte loss
  • Ketoacids (pK < 4.0) produce severe metabolic acidosis → Diabetic Ketoacidosis (DKA)
Without treatment, DKA leads to death.
  • Medical Physiology, p. 3592-3596

Key Features Summary

  • C-peptide: Very low or undetectable (marker of absent endogenous insulin)
  • Insulin: Absent
  • Body habitus: Usually lean
  • DKA risk: High - life-threatening
  • Treatment: Insulin replacement is mandatory and lifelong

Type 2 Diabetes Mellitus

Definition and Epidemiology

Type 2 DM is the most common form, affecting >537 million adults worldwide (2021 estimate, projected to reach 783 million by 2045). In the U.S., it accounts for ~10.5% of the total adult population. It arises from an interaction between hereditary predisposition and environmental factors, primarily obesity and sedentary lifestyle.
  • Goldman-Cecil Medicine, p. 814-816

Core Pathophysiology: A Dual Defect

Type 2 DM results from two primary, interacting metabolic abnormalities:

1. Insulin Resistance (Primary, Early Defect)

Resistance to insulin's action occurs primarily in:
  • Skeletal muscle - reduced glucose uptake (GLUT-4 translocation impaired)
  • Adipose tissue - enhanced lipolysis, elevated free fatty acids
  • Liver - inadequate suppression of hepatic glucose output
This insulin resistance is strongly linked to obesity, particularly visceral adiposity. The mechanism involves:
  • Elevated circulating free fatty acids from excess adipose tissue interfere with intracellular insulin signaling (serine phosphorylation of IRS-1)
  • Adipokine dysregulation (reduced adiponectin, elevated leptin resistance, elevated TNF-α and IL-6 from adipose tissue)
  • Ectopic fat deposition in liver and muscle ("lipotoxicity")
Initially, insulin resistance stimulates compensatory hyperinsulinemia - β cells overproduce insulin to maintain normal glucose levels. Glucose tolerance remains normal during this compensated phase.
  • Goldman-Cecil Medicine, p. 874-875

2. β-Cell Dysfunction and Exhaustion (Progressive)

As insulin resistance persists, β-cell function deteriorates:
  • By the time of diagnosis, up to 50% of β-cell mass may already have failed
  • Early dysfunction includes: diminished pulsatile and oscillatory insulin release, downregulation of the pancreatic insulin receptor
  • Islet amyloid polypeptide (IAPP/amylin) accumulation contributes to β-cell loss
  • Unlike Type 1, β cells are initially hyperplastic as they compensate, but eventually become exhausted ("pancreatic exhaustion" → insulinopenia)
  • The progressive decline in β-cell secretory capacity means that many long-standing Type 2 DM patients ultimately require insulin
The relative contribution of insulin resistance vs. β-cell failure varies between individuals and changes over time in the same individual.
  • Goldman-Cecil Medicine, p. 825-826; Medical Physiology, p. 3601

Why DKA Usually Does Not Occur in Type 2

In Type 2 DM, residual insulin secretion is sufficient to suppress complete hepatic ketogenesis, even if inadequate to normalize blood glucose. This is why hyperglycemic hyperosmolar state (HHS) - rather than DKA - is the characteristic acute complication of Type 2 DM.
  • Medical Physiology, p. 3601; Miller's Anesthesia, p. 877

Genetics of Type 2 DM

  • Strongly polygenic - >100 genetic risk loci identified, collectively explaining <15% of heritability
  • Twin concordance: 70% in monozygotic twins (much higher than Type 1 ~50%)
  • Family history: 40% lifetime risk with one affected parent; 70% with both parents
  • Key susceptibility gene: TCF7L2 (strongest effect; odds ratio 1.4) - associated with reduced insulin secretion
  • Other loci: ZnT-8 (β-cell zinc transporter), KCNJ11 (sulfonylurea receptor / K-ATP channel), MTNR1B (melatonin receptor), PPARγ (insulin sensitivity), IRS-1
  • Goldman-Cecil Medicine, p. 878-889

Metabolic Syndrome Association

Insulin resistance in Type 2 DM brings a cluster of metabolic abnormalities known as metabolic syndrome:
  • Hypertension
  • Obesity (especially central/visceral)
  • Dyslipidemia: elevated triglycerides + depressed HDL-cholesterol
  • Increased atherosclerotic cardiovascular risk
This constellation of abnormalities is estimated to affect >45 million individuals in the United States.
  • Medical Physiology, p. 3603

Side-by-Side Comparison

FeatureType 1 DMType 2 DM
MechanismAutoimmune β-cell destructionInsulin resistance + β-cell dysfunction
Insulin levelAbsent (absolute deficiency)Present but insufficient (relative deficiency)
C-peptideVery low/undetectableNormal to elevated early; falls later
β-cell massSeverely depletedReduced (~50% at diagnosis)
AutoantibodiesPresent (GAD65, IAA, IA-2, ZnT8A)Absent
HLA associationDR3/DR4 strongly associatedWeak/absent
Body habitusUsually leanUsually overweight/obese
Age of onsetTypically childhood/young adultTypically adult (but increasing in youth)
DKA riskHighLow (HHS more typical)
GlucagonElevated/unopposedMildly elevated
Insulin resistanceNot primaryPrimary and early
GeneticsHLA-dominated; moderate concordancePolygenic; high twin concordance (70%)
TreatmentInsulin always requiredLifestyle, oral agents, eventually insulin

Shared Long-Term Complications

Both types share identical chronic microvascular and macrovascular complications, all driven by prolonged hyperglycemia:
  • Diabetic retinopathy - microvascular damage to retinal capillaries
  • Diabetic nephropathy - glomerular injury, proteinuria, progressive renal failure
  • Peripheral neuropathy - axonal damage from chronic glucose exposure
  • Accelerated atherosclerosis - ischemic heart disease, peripheral artery disease, stroke
Tight glycemic control alongside blood pressure and lipid management significantly reduces the progression of these complications in both types.
  • Medical Physiology, p. 3595-3605
Sources: Medical Physiology (Boron & Boulpaep); Goldman-Cecil Medicine, 2-Volume Set; Cellular and Molecular Immunology (Abbas et al.); Henry's Clinical Diagnosis and Management by Laboratory Methods; Harrison's Principles of Internal Medicine 22e
This is a shared conversation. Sign in to Orris to start your own chat.